ArticleEuropean journal of clinical investigation2026
Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for COVID-19 vaccines in 2024 in Austria.
Article in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for COVID-19 vaccines in 2024 in Austria.European journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPost-pandemic years are characterized by widespread previous population immunization against COVID-19. Whether and for whom COVID-19 vaccinations are still justified is unclear. We use nationwide estimates of IFR and literature-derived estimates of vaccine effectiveness (VE) to calculate numbers needed to vaccinate to prevent one COVID-19 death (NNV) and for one life-year saved (LYS) in Austria in 2024.
methodsIn this retrospective analysis, we calculate SARS-CoV-2 IFR during 2024 in Austria according to previously published wastewater-based infection estimates and available mortality data. Using literature-derived VE estimates, we calculate NNV to prevent one COVID-19 death and for one LYS in strata according to age groups, nursing home residency and vaccination in 2024. We repeat analyses with sensitivity range values of parameters.
resultsIn 2024, total IFR was .048%. NNV (LYS) in the age groups 0-19, 20-39, 40-59, 60-74 and 75-84 years was very high: i.e. 5,497,526 (151,570), 2,432,498 (92,614), 415,714 (24,777), 35,925 (3748) and 4882 (1009), respectively, in community dwellers. In the 85+ years age group, IFRs of unvaccinated/vaccinated were .91%/.77% for community dwellers and 1.22%/1.04% for nursing home residents. The 85+ year age group had NNV estimates of 1215 and 907 (LYS: 525 and 1896) in community dwellers and nursing home residents, respectively. Sensitivity analyses yielded LYS < 1000 only under some favourable assumptions in the 75-84 and 85+ years old age strata.
conclusionsIn 2024 in Austria, SARS-CoV-2 IFR was low and NNV and LYS of COVID-19 vaccinations correspondingly non-favorably high, even for very old individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.